Gut microbial imbalance tracks with immune activation in ankylosing spondylitis

A new analysis in ankylosing spondylitis ties intestinal dysbiosis to the immune features that shape this inflammatory disease. In 62 patients with AS and 62 healthy controls, fecal 16S rRNA sequencing showed a clear reduction in microbial diversity alongside a redistribution of major bacterial groups. The pattern was not subtle: taxa typically associated with gut homeostasis fell away, while organisms linked to inflammatory or opportunistic behavior became more prominent.

The work matters because AS is not confined to joints and entheses. The disease sits at the intersection of mucosal immunity, systemic inflammation, and host-microbe signaling, and this study adds another layer by connecting bacterial composition to peripheral lymphocyte subsets, serum cytokines, and standard activity markers.

Loss of diversity and expansion of inflammatory taxa

Compared with healthy controls, patients with AS had significantly lower microbial diversity. At the phylum level, Proteobacteria and Patescibacteria were enriched, while Firmicutes, Fusobacteriota, and Verrucomicrobiota were depleted. The genus-level shifts were even more clinically intuitive. Escherichia–Shigella increased, whereas Faecalibacterium, Prevotella, Agathobacter, Roseburia, and Dialister declined. Among the higher-order bacterial signals, Enterobacterales emerged as the most discriminant order.

One sentence captures the biological direction of travel: the microbiome in AS looked less resilient and more inflamed.

These shifts fit a familiar immunologic model. Reduced abundance of short-chain fatty acid–associated commensals such as Faecalibacterium, Agathobacter, and Roseburia may weaken epithelial stability and mucosal immune regulation, while expansion of Enterobacterales and Escherichia–Shigella may reflect a gut environment more permissive to inflammatory signaling. The study does not prove causality, but the pattern is consistent with a microbiome capable of amplifying rather than damping immune tone.

Bacterial signals aligned with lymphocyte subsets and cytokines

The most clinically useful part of the study is the correlation matrix linking individual taxa to host immune markers. Agathobacter and Prevotella showed positive correlations with CD4+ T cells, Th1, Th2, and Th17 cells. In contrast, Escherichia–Shigella correlated negatively with Th2 cells.

Those associations point to a bidirectional mucosal-immune dialogue. Th17 biology has long been central to spondyloarthritis, and a gut ecosystem linked to Th17 expansion or persistence offers a plausible path from intestinal perturbation to systemic inflammation. The inverse relationship between Escherichia–Shigella and Th2 cells may also reflect immune skewing away from counter-regulatory pathways, although the study design cannot determine whether microbial change precedes immune imbalance or follows it.

Serum cytokine testing added another important dimension. Distinct gut taxa were significantly associated with both proinflammatory and anti-inflammatory mediators, including IL-2, IL-6, IL-17, and IL-10. In practical terms, the microbiome did not merely correlate with a single inflammatory readout; it tracked with a broader cytokine network that includes both activation and regulation. For a disease like AS, where inflammatory signaling is distributed across multiple axes, that breadth strengthens the case that gut ecology and systemic immune activation are coupled.

Disease activity markers moved with the microbiome

Correlations extended beyond immune phenotyping to clinical activity itself. Specific taxa were significantly associated with ESR, CRP, and ASDAS-CRP scores. Those three measures matter because they anchor the biologic signal to routine bedside assessment. ESR and CRP reflect systemic inflammation, while ASDAS-CRP integrates symptoms with biomarker burden to estimate disease activity in a way clinicians actually use.

The result is a more integrated picture of AS than a simple case-control comparison. Microbial depletion and expansion were not isolated laboratory curiosities; they moved in step with peripheral immune subsets, cytokine profiles, and disease activity indices. In a condition where inflammation may begin in the gut and declare itself in the axial skeleton, that alignment is clinically coherent.

What this means for ankylosing spondylitis care

This study reinforces the idea that AS should be viewed partly through a mucosal immunology lens. Altered gut microbiota could contribute to the persistence of systemic inflammation by shaping antigen exposure, epithelial barrier function, and the balance between effector and regulatory immune responses. The findings around Proteobacteria, Enterobacterales, and Escherichia–Shigella support a proinflammatory microbial signature, while the loss of Faecalibacterium, Roseburia, and related genera suggests erosion of taxa often associated with metabolic and immunologic stability.

For clinicians, the immediate value is conceptual rather than therapeutic. These data do not justify microbiome-targeted treatment decisions on their own, and the abstract does not provide longitudinal outcomes, treatment response data, or interventional evidence. What it does provide is a biologically plausible map linking gut ecology to the immune markers that already guide AS assessment.

Several questions remain open. The sample was modest, the analysis was cross-sectional, and the sequencing approach captures associations rather than causal direction. Medication exposure, diet, and other unmeasured environmental factors may also influence microbial composition. Even so, the consistency across taxa, lymphocyte subsets, cytokines, and disease activity measures gives the study a clear internal logic.

For now, the take-home message is concrete: in ankylosing spondylitis, the gut microbiome appears less diverse, more dysbiotic, and more closely tied to inflammatory immune signatures than in healthy controls. Whether that signature can be used to stratify patients, predict flare risk, or guide future microbiome-directed therapy will require longitudinal and interventional studies.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by Frontiers in Immunology.